Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: Comparative analysis of response to treatments and molecular features of tumor-derived organoids versus cell lines and PDX derived from the same ovarian clear cell carcinoma

Fig. 4

PDX and PDTO recapitulate the clinical response of the patient. A, B and C Cell lines (L, OL, XL, XOL and reference) response to carboplatin, gemcitabine and doxorubicin, respectively. D, E and F PDTO (O, XO and reference) response to carboplatin, gemcitabine and doxorubicin respectively. G, H and I PDTO (O, XO and reference) morphology in response to carboplatin, gemcitabine and doxorubicin respectively at day 0, day 3 and day 6. C = control, scale bar: 200 µm. J, K and L PDX (X) response to carboplatin, gemcitabine and doxorubicin respectively. M Summary of the PDX, PDTO and cell lines sensitivity to treatments compared to the patient clinical response

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us